Breaking News

Tweet TWEET

Omnicare and AmerisourceBergen Under Review: Drugs Company Stocks Hit New Highs

  Omnicare and AmerisourceBergen Under Review: Drugs Company Stocks Hit New
                                    Highs

  PR Newswire

  LONDON, February 21, 2013

LONDON, February 21, 2013 /PRNewswire/ --

Health-care reforms are expected to bring about paradigm shift in healthcare
sectors. However, the major companies are well prepared for such changes.
Among others, wholesale drug companies are looking to consolidate their
positions in order to be better equipped to face challenges. The stocks are
trading on their highs on account of the good performance. AmerisourceBergen
Corporation (NYSE: ABC) reported good results and a new collaboration with
PharMerica. Similarly, Omnicare Inc. (NYSE: OCR) is getting lapped up Hedge
Funds. The stocks are expected to keep up the momentum and perform well.
StockCall has released free charting and technical research on these two
aforementioned companies. Register to read these reports at

http://www.stockcall.com/report 

AmerisourceBergen Inks Deal with Express Script

AmerisourceBergen's stock hit a new 52-week high. The stock is up 28 percent
in the past 52 weeks and seems to maintain the streak. The company also
recently announced a 21 cent per share dividend payable on March 4 ^th . Its
dividend yield stands at 1.80 percent. AmerisourceBergen reported its fiscal
first quarter revenue at $21.5 billion, up 5 percent from $20.3 billion
reported a year earlier. Its net income also increased from 62 cents per share
to 71 cents apiece. For fiscal 2013, the company expects its earnings to be at
$3.16 per share, beating expectations of $3.13 per share. AmerisourceBergen
Corporation free technical report can be accessed by signing up at
http://www.StockCall.com/ABC022113.pdf 

AmerisourceBergen is expected to keep performing well as the company won a
major contract with Express Scripts. The company also renewed its deal with
PharMerica, which ensure that the company remains the primary vendor for
pharmaceuticals for PharMerica. The deal also makes AmerisourceBergen the
primary vendor for California-based Amerita.

AmerisourceBergen is expected to face some tailwinds once health reforms kick
in. It also has thin margins and therefore has lesser cushion. However, the
company stock is expected to perform well despite its recent run up.

Omnicare Garners Hedge Fund Interest

Omnicare reported good results for its fourth quarter. The company reported
its EPS at 86 cents per share, up from 56 cents per share it had reported a
year earlier. Its revenue stood at $1.53 billion, down 1.74 percent. The stock
has been hitting new 52-week highs lately. It had also been garnering good
institutional interest as well. Hedge fund Iridian Asset Management augmented
its holding of the company's stock. Omnicare's stock is also held by First
Pacific Advisors. Hedge Fund buying is generally considered to be a positive
sign for the future growth of the stock. Another major holder of the stock is
Oaktree Capital Management. Sign up for the free report on Omnicare Inc. at
http://www.StockCall.com/OCR022113.pdf 

However, Omnicare faces some challenges as well. The company is currently
restructuring its business to curtail its costs. Late last year, it closed
some of its offices and reduced headcounts. It also changed its top management
and made some key appointments. The company deals in pharmaceutical care and
is mainly operational in Canada and the U.S. It also operates chronic care
facilities.

Omnicare's stock gained 6 percent this year so far and is up 11 percent in the
past 12 months. The stock also offers 1.45 percent dividend yield. Omnicare
recently announced 14 cents per share in quarterly dividend.

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at http://www.stockcall.com

Contact: William T. Knight, Email: info@stockcall.com, Contact Number:
+1-646-396-9857 (9:00 am EST - 01:30 pm EST)
 
Press spacebar to pause and continue. Press esc to stop.